Evercore ISI Group Downgrades CRISPR Therapeutics to In-Line, Lowers Price Target to $52

Evercore ISI Group analyst Ravi Mehrotra downgrades CRISPR Therapeutics (NASDAQ:CRSP) from Outperform to In-Line and lowers the price target from $85 to $52.

Benzinga · 02/03/2020 11:32

Evercore ISI Group analyst Ravi Mehrotra downgrades CRISPR Therapeutics (NASDAQ:CRSP) from Outperform to In-Line and lowers the price target from $85 to $52.